News | August 10, 2008

Flexible Stenting Solutions Completes First Human Study of New Peripheral Arterial Stent

August 11, 2008 - Flexible Stenting Solutions Inc. said today a physician at Auckland City Hospital in New Zealand successfully implanted several of its third generation arterial stents for the treatment of peripheral vascular lesions involving the superficial femoral and popliteal arteries.

Patients with lesion lengths up to 100 mm and fully occluded lesions were included in the study.

This first-in-man clinical trial using a full range of stent sizes, including 120 mm, was performed by Associate Professor Andrew Holden who is the director of interventional radiology at Auckland City Hospital, and the principal investigator.

“The flexible stent handled both stenoses and occlusions in the femoro-popliteal artery segment as well as I had hoped with excellent immediate appearances following deployment” Holden said. “Overall, I felt the stent and delivery system performed very well in the acute phase and I await the longer term follow up in these patients with great interest.”

Flexible Stenting Solutions has developed a novel, self-expanding stent technology to provide a wide range of vascular and non-vascular therapies. The treatment of femoro-popliteal disease is the first vascular application of Flexible Stenting Solutions’ technology.

While stent procedures have become widespread in the treatment of coronary arterial disease, their use in the more challenging peripheral vascular disease setting had been limited in the last several years by inadequate stent design, the company said. The fully connected SFA/Pop flexible stent has coupled technology with clinical needs by reportedly providing a highly durable and fatigue resistant stent with superior radial stiffness and low chronic outward force.

For more information: www.flexiblestent.com


Related Content

News | Cardiovascular Clinical Studies

September 8, 2022 — A clinical trial led by investigators from Brigham and Women’s Hospital has found that the long-term ...

Home September 08, 2022
Home
News | Cardiovascular Clinical Studies

August 17, 2022 — A study carried out by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) ...

Home August 17, 2022
Home
News | Cardiovascular Clinical Studies

August 12, 2022 — Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at ...

Home August 12, 2022
Home
News | Cardiovascular Clinical Studies

August 8, 2022 — Two years ago, University of Alabama at Birmingham researchers and colleagues reported that reductive ...

Home August 08, 2022
Home
News | Cardiovascular Clinical Studies

July 22, 2022 — BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by ...

Home July 22, 2022
Home
News | Cardiovascular Clinical Studies

July 18, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that ...

Home July 19, 2022
Home
News | Cardiovascular Clinical Studies

July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details ...

Home July 15, 2022
Home
News | Cardiovascular Clinical Studies

July 11, 2022 — Smoking traditional or non-combustible cigarettes while wearing a surgical mask results in a two-fold ...

Home July 12, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
Subscribe Now